{"id":"W2944165579","doi":"10.1158/1538-7445.sabcs18-p1-13-05","title":"Abstract P1-13-05: Efficacy and safety of eflapegrastim confirmed in reducing severe neutropenia in breast cancer patients treated with myelosuppressive chemotherapy in the second Phase 3 randomized controlled multinational trial compared to pegfilgrastim (RECOVER trial)","year":2019,"lang":"en","type":"article","venue":"Cancer Research","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Pegfilgrastim; Medicine; Neutropenia; Docetaxel; Breast cancer; Internal medicine; Febrile neutropenia; Clinical endpoint; Cyclophosphamide; Oncology; Phases of clinical research; Chemotherapy; Cancer; Surgery; Clinical trial","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001794095,0.0002948074,0.001766631,0.0006590695,0.00008514404,0.00005484084,0.0002184745,0.0001231997,0.002952156],"category_scores_gemma":[0.0002239839,0.0001849201,0.0001353959,0.001005388,0.0002529095,0.0001534855,0.00004125272,0.0007667493,0.000005545563],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005461277,"about_ca_system_score_gemma":0.0009122586,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.005456289,"about_ca_topic_score_gemma":0.003670546,"domain_scores_codex":[0.9962599,0.0008377458,0.0009866605,0.000581722,0.0008001942,0.0005338238],"domain_scores_gemma":[0.9966474,0.002118588,0.0002763999,0.0003097887,0.0004893344,0.000158446],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9704766,0.001773685,0.01537998,0.0001108402,0.0002267725,0.00001922962,0.001493143,0.0008165028,0.007382055,0.000007720574,0.0003779579,0.001935552],"study_design_scores_gemma":[0.8396253,0.001088622,0.1567773,0.0007650614,0.00005342967,0.000006274346,0.0002099151,0.000273737,0.0008806188,0.000004033359,0.0001462289,0.0001694201],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9781307,0.0001266766,9.472161e-7,0.001398472,0.0001823699,0.01895951,0.0002795372,0.00001026721,0.0009115115],"genre_scores_gemma":[0.9952062,0.0001680737,0.00001020904,0.0001788973,0.0001483994,0.003781709,0.00006613681,0.00003837145,0.000401954],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1413974,"threshold_uncertainty_score":0.9979593,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02701083480219315,"score_gpt":0.3725926572760232,"score_spread":0.3455818224738301,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}